Feb 28, 2019 · ResVax is being developed to protect infants via maternal immunization against RSV disease. In the Prepare trial, efficacy of ResVax against the primary and two secondary endpoints in per-protocol infants with RSV lower respiratory tract infection (LRTI) through 90 days of …

Sep 15, 2016 · The primary objective of the Resolve trial was to demonstrate efficacy in the prevention of moderate-severe RSV-associated lower respiratory tract disease (RSV msLRTD), as defined by the presence of multiple lower respiratory tract symptoms.

Apr 5, 2023 · RSVpreF vaccine prevented RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults (≥60 years of age), without evident safety concerns.

Aug 12, 2019 · ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is designed to prevent severe lower respiratory tract infection which is the second leading cause of death in children under one year of age worldwide.

Mar 1, 2019 · Novavax has reported negative top-line results from the Phase III Prepare clinical trial of its ResVax vaccine being developed to prevent respiratory syncytial virus (RSV) disease in infants through maternal immunisation.

Jul 29, 2020 · RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success criterion for efficacy against RSV-associated, medically significant lower respiratory tract...

Jun 27, 2017 · Objective: Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants. We are developing an RSV fusion (F) protein nanoparticle vaccine for immunization of third trimester pregnant women to passively protect infants through transfer of RSV-specific maternal antibodies.

Feb 28, 2019 · ResVax is being developed to protect infants via maternal immunization against RSV disease. In the Prepare trial, efficacy of ResVax against the primary and two secondary endpoints...

Jul 30, 2020 · RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success criterion for efficacy against RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of life.

Oct 5, 2011 · A Phase I clinical study conducted by Novavax has demonstrated positive top-line results of its respiratory syncytial virus (RSV) fusion (F) recombinant nanoparticle vaccine candidate.